Intravenous Cardiac Stem Cell-Derived Exosomes Ameliorate Cardiac Dysfunction in Doxorubicin Induced Dilated CardiomyopathyReportar como inadecuado

Intravenous Cardiac Stem Cell-Derived Exosomes Ameliorate Cardiac Dysfunction in Doxorubicin Induced Dilated Cardiomyopathy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Stem Cells International - Volume 2015 2015, Article ID 960926, 8 pages -

Research Article

Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27695, USA

Joint Department of Biomedical Engineering, UNC-Chapel Hill and NC State University, Chapel Hill and Raleigh, NC, USA

Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhengzhou University, Zhengzhou, Henan 450052, China

Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

The Cyrus Tang Hematology Center, Soochow University, Suzhou 215123, China

Received 20 April 2015; Accepted 7 June 2015

Academic Editor: Tao-Sheng Li

Copyright © 2015 Adam C. Vandergriff et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Despite the efficacy of cardiac stem cells CSCs for treatment of cardiomyopathies, there are many limitations to stem cell therapies. CSC-derived exosomes CSC-XOs have been shown to be responsible for a large portion of the regenerative effects of CSCs. Using a mouse model of doxorubicin induced dilated cardiomyopathy, we study the effects of systemic delivery of human CSC-XOs in mice. Mice receiving CSC-XOs showed improved heart function via echocardiography, as well as decreased apoptosis and fibrosis. In spite of using immunocompetent mice and human CSC-XOs, mice showed no adverse immune reaction. The use of CSC-XOs holds promise for overcoming the limitations of stem cells and improving cardiac therapies.

Autor: Adam C. Vandergriff, James Bizetto Meira de Andrade, Junnan Tang, M. Taylor Hensley, Jorge A. Piedrahita, Thomas G. Caranasos



Documentos relacionados